National Cancer Institute Awards Tosk $2 Million Cancer Drug Development Grant

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Tosk, Inc. announced today that it has received a two-year, $2 million
Phase II SIBR grant from the National Cancer Institute (NCI) to support
its kRAS oncogene drug research and development program, a high priority
for the NCI.

Some 40 percent of all cancer patients carry an oncogenic kRAS gene that
renders EGFR-inhibitor cancer therapies, such as Erbitux®,
ineffective. Tosk is working on drugs to address this problem and make
this important class of cancer therapies effective in patients who do
not currently benefit. Such a drug could also be effective in treating
kRAS positive cancers, such as many pancreatic, colon, lung, and other

“The objective of our kRAS program,” according to Tosk’s CEO, drug
industry veteran Brian Frenzel, “is to develop drugs to selectively
block the activity of oncogenic kRAS. Tosk has improvised a proprietary
drug screening technology using genetically modified fruit flies to
identify drugs with this capability.”

A portion of Tosk’s kRAS program was financed by a Phase I SBIR research
grant from NCI. The Company is collaborating with the Texas Tech
University Health Sciences Center on this program through Tosk’s
Scientific Advisory Board member, Professor Jeff Thomas.

Tosk’s scientists have worked for a decade to develop innovative
technologies that use the fruit fly as a model for human diseases. The
effort to develop a kRAS drug is one of four important research programs
underway at Tosk. The other programs are focused on developing cost
effective, small molecule drugs that reduce or eliminate the adverse
side effects of existing, front-line cancer therapies. Tosk believes
that its drug candidates will not only improve outcomes for cancer
patients, but reduce the overall cost of care. The first of these drugs
began human trials in cancer patients in 2017.


Tosk, Inc.
Brian Frenzel, +1 408-245-6838